Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-?) mediated killing by contacting the cells or administering the agent that inhibits autophagy.

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

Abstract: A system, method, and computer program product for self-identification of a device. The disclosure utilizes generation of a public/private key pair, within the device itself, and completes at least a portion of an authentication process within the device itself using a securely stored private key that never leaves the device. By not transferring the private key away from the device, potential vulnerabilities of known systems due to transfer of identification information during or after manufacturing is effectively eliminated.

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

Abstract: An ophthalmological teaching aid includes a shell having an outer surface, an interior, a student region with a viewing window, and an observation target in the interior of the shell. The observation target is positioned to be visible to a viewer looking through the viewing window and has at least one feature residing at a feature location. The teaching aid also includes an instructor region spatially corresponding to at least a portion of the observation target. The teaching aid includes a landmark corresponding to the feature location. The presence of the landmark enables the instructor to assess a student's skill in using an ophthalmoscope.

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1-Fc-F1 or AngF2-Fc-F2.

Abstract: An ophthalmological teaching aid includes a shell having an outer surface, an interior, a student region with a viewing window, and an observation target in the interior of the shell. The observation target is positioned to be visible to a viewer looking through the viewing window and has at least one feature residing at a feature location. The teaching aid also includes an instructor region spatially corresponding to at least a portion of the observation target. The teaching aid includes a landmark corresponding to the feature location. The presence of the landmark enables the instructor to assess a student's skill in using an ophthalmoscope.

Abstract: An oxidation catalyst is described for treating an exhaust gas produced by a diesel engine comprising a catalytic region and a substrate, wherein the catalytic region comprises a catalytic material comprising: bismuth (Bi), antimony (Sb) or an oxide thereof; a platinum group metal (PGM) selected from the group consisting of (i) platinum (Pt), (ii) palladium (Pd) and (iii) platinum (Pt) and palladium (Pd); and a support material, which is a refractory oxide; wherein the platinum group metal (PGM) is supported on the support material; and wherein the bismuth (Bi), antimony (Sb) or an oxide thereof is supported on the support material and/or the refractory oxide comprises the bismuth, antimony or an oxide thereof.

Abstract: An oxidation catalyst is described for treating an exhaust gas produced by a diesel engine comprising a catalytic region and a substrate, wherein the catalytic region comprises a catalytic material comprising: bismuth (Bi), antimony (Sb) or an oxide thereof; a platinum group metal (PGM) selected from the group consisting of (i) platinum (Pt), (ii) palladium (Pd) and (iii) platinum (Pt) and palladium (Pd); and a support material, which is a refractory oxide; wherein the platinum group metal (PGM) is supported on the support material; and wherein the bismuth (Bi), antimony (Sb) or an oxide thereof is supported on the support material and/or the refractory oxide comprises the bismuth, antimony or an oxide thereof.

Abstract: An oxidation catalyst is described for treating an exhaust gas produced by a diesel engine comprising a catalytic region and a substrate, wherein the catalytic region comprises a catalytic material comprising: bismuth (Bi) or an oxide thereof; an alkaline earth metal or an oxide thereof; a platinum group metal (PGM) selected from the group consisting of (i) platinum (Pt), (ii) palladium (Pd) and (iii) platinum (Pt) and palladium (Pd); and a support material comprising alumina doped with silica in a total amount of 0.5 to 15% by weight of the alumina.

Abstract: An oxidation catalyst for treating an exhaust gas produced by a compression ignition engine comprising: a substrate; a catalytic material disposed on the substrate, wherein the catalytic material comprises platinum (Pt); and a region comprising a capture material, wherein the region is arranged to contact the exhaust gas after the exhaust gas has contacted and/or passed through the catalytic material.

Abstract: The present invention provides methods for inhibiting or attenuating the growth of a tumor that is resistant to a blockade of EGFR, which include administering an EGFR inhibitor, an EGFR inhibitor and a FGFR inhibitor, or an EGFR inhibitor, an FGFR inhibitor and an ErbB3 inhibitor to a subject having a tumor that is or may become resistant to the blockade of EGFR. Blockade of EGFR, FGFR and/or ErbB3 may be effectuated using target specific antibodies or fragments thereof, small molecule tyrosine kinase inhibitors or a combination thereof.

Abstract: The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1-Fc-F1 or AngF2-Fc-F2.

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.